Top

Breast Cancer

Published in:

01-07-2018 | Original Article

OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer

Authors: Jia-Ming Zhang, Kai Wei, Ming Jiang

Published in: Breast Cancer | Issue 4/2018

Abstract

Background

Octamer-binding transcription factor 4 (OCT4) and SRY (sex determining region Y)-box 2 (SOX2) are common biomarkers of cancer stem cells, which contribute to the pathological processes of several carcinomas, while little is known about the effects of OCT4 and SOX2 on the prognosis of triple-negative breast cancer (TNBC). The purpose was to evaluate the correlation of tumor tissue OCT4 and SOX2 expressions with clinicopathological features and overall survival (OS) in surgical TNBC patients.

Methods

127 surgical patients with TNBC were enrolled in this cohort study. Tumor tissue samples were obtained during the operation. OCT4 and SOX2 expressions were assessed by immunofluorescent staining.

Results

32 (25%) TNBC patients with OCT4 positive expression (OCT4⁺), 21 (17%) patients with SOX2 positive expression (SOX2⁺), and 11 (9%) patients with both OCT4⁺ and SOX2⁺ were observed. OCT4 expression was positively associated with histologic grade (P < 0.001), pathological tumor size (P = 0.014), N stage (P < 0.001) and TNM stage (P < 0.001), while SOX2 expression was positively correlated with histologic grade (P < 0.001), pathological tumor size (P = 0.033) and Ki-67 expression (P = 0.016). Kaplan–Meier (K–M) curves suggested OCT4⁺ was correlated with shorter OS compared with OCT4⁻ (P < 0.001), while no correlation between SOX2⁺ with OS in all patients (P = 0.128) was observed. Multivariate Cox model indicated that OCT4⁺ (P < 0.001) were independent factors for worse OS.

Conclusions

Tumor tissue OCT4 but not SOX2 expression was positively correlated with histologic grade, pathological tumor size, N stage and TNM stage, and it could be served as an independent biomarker to predict worse prognosis in surgical patients with TNBC.

Available only for authorised users

Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–50. https://doi.org/10.1016/S0140-6736(16)31891-8.CrossRefPubMed

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.CrossRefPubMed

Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363(20):1938–48. https://doi.org/10.1056/NEJMra1001389.CrossRefPubMed

Brewster AM, Chavez-MacGregor M, Brown P. Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. Lancet Oncol. 2014;15(13):e625–34. https://doi.org/10.1016/S1470-2045(14)70364-X.CrossRefPubMedPubMedCentral

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67. https://doi.org/10.1172/JCI45014.CrossRefPubMedPubMedCentral

Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer. 2013;13(10):727–38. https://doi.org/10.1038/nrc3597.CrossRefPubMed

Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer. 2012;12(11):767–75. https://doi.org/10.1038/nrc3368.CrossRefPubMed

Yu L, Jiao YJ, Zhou L, Song WQ, Wu SW, Wang DN. Expressions of OCT4, Notch1 and DLL4 and their clinical implications in epithelial ovarian cancer. Nan Fang Yi Ke Da Xue Xue Bao. 2016;37(4):444–50.PubMed

Stewart CJ, Crook ML. Podoplanin and SOX2 expression in CIN 3-like squamous cell carcinoma of the cervix. Int J Gynecol Pathol. 2017. https://doi.org/10.1097/PGP.0000000000000383.CrossRefPubMed

10.

Zhong F, Cheng X, Sun S, Zhou J. Transcriptional activation of PD-L1 by SOX2 contributes to the proliferation of hepatocellular carcinoma cells. Oncol Rep. 2017;37(5):3061–7. https://doi.org/10.3892/or.2017.5523.CrossRefPubMed

11.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–10.CrossRefPubMed

12.

Budwit-Novotny DA, McCarty KS, Cox EB, Soper JT, Mutch DG, Creasman WT, et al. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 1986;46(10):5419–25.PubMed

13.

Lessey BA, Castelbaum AJ, Sawin SW, Buck CA, Schinnar R, Bilker W, et al. Aberrant integrin expression in the endometrium of women with endometriosis. J Clin Endocrinol Metab. 1994;79(2):643–9. https://doi.org/10.1210/jcem.79.2.7519194.PubMedCrossRef

14.

Elnemr GM, El-Rashidy AH, Osman AH, Issa LF, Abbas OA, Al-Zahrani AS, et al. Response of triple negative breast cancer to neoadjuvant chemotherapy: correlation between Ki-67 expression and pathological response. Asian Pac J Cancer Prev. 2016;17(2):807–13.CrossRefPubMed

15.

Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28(10):1684–91. https://doi.org/10.1200/JCO.2009.24.9284.CrossRefPubMed

16.

Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer. 2007;7:134. https://doi.org/10.1186/1471-2407-7-134.CrossRefPubMedPubMedCentral

17.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14(5):1368–76. https://doi.org/10.1158/1078-0432.CCR-07-1658.CrossRefPubMed

18.

Kashyap V, Rezende NC, Scotland KB, Shaffer SM, Persson JL, Gudas LJ, et al. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev. 2009;18(7):1093–108. https://doi.org/10.1089/scd.2009.0113.CrossRefPubMedPubMedCentral

19.

Cheng J, Li W, Kang B, Zhou Y, Song J, Dan S, et al. Tryptophan derivatives regulate the transcription of OCT4 in stem-like cancer cells. Nat Commun. 2015;6:7209. https://doi.org/10.1038/ncomms8209.CrossRefPubMedPubMedCentral

20.

Hu J, Qin K, Zhang Y, Gong J, Li N, Lv D, et al. Downregulation of transcription factor OCT4 induces an epithelial-to-mesenchymal transition via enhancement of Ca²⁺ binflux in breast cancer cells. Biochem Biophys Res Commun. 2011;411(4):786–91. https://doi.org/10.1016/j.bbrc.2011.07.025.CrossRefPubMed

21.

Kim RJ, Nam JS. OCT4 expression enhances features of cancer stem cells in a mouse model of breast cancer. Lab Anim Res. 2011;27(2):147–52. https://doi.org/10.5625/lar.2011.27.2.147.CrossRefPubMedPubMedCentral

22.

Wang YD, Cai N, Wu XL, Cao HZ, Xie LL, Zheng PS. OCT4 promotes tumorigenesis and inhibits apoptosis of cervical cancer cells by miR-125b/BAK1 pathway. Cell Death Dis. 2013;4:e760. https://doi.org/10.1038/cddis.2013.272.CrossRefPubMedPubMedCentral

23.

Jen J, Tang YA, Lu YH, Lin CC, Lai WW, Wang YC. OCT4 transcriptionally regulates the expression of long non-coding RNAs NEAT1 and MALAT1 to promote lung cancer progression. Mol Cancer. 2017;16(1):104. https://doi.org/10.1186/s12943-017-0674-z.CrossRefPubMedPubMedCentral

24.

Hatefi N, Nouraee N, Parvin M, Ziaee SA, Mowla SJ. Evaluating the expression of Oct4 as a prognostic tumor marker in bladder cancer. Iran J Basic Med Sci. 2012;15(6):1154–61.PubMedPubMedCentral

25.

Gwak JM, Kim M, Kim HJ, Jang MH, Park SY. Expression of embryonal stem cell transcription factors in breast cancer: OCT4 as an indicator for poor clinical outcome and tamoxifen resistance. Oncotarget. 2017;8(22):36305–18. https://doi.org/10.18632/oncotarget.16750.CrossRefPubMedPubMedCentral

26.

Linn DE, Yang X, Sun F, Xie Y, Chen H, Jiang R, et al. A role for OCT4 in tumor initiation of drug-resistant prostate cancer cells. Genes Cancer. 2010;1(9):908–16. https://doi.org/10.1177/1947601910388271.CrossRefPubMedPubMedCentral

27.

Li B, Yao Z, Wan Y, Lin D. Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer. Oncotarget. 2016;7(47):77342–7. https://doi.org/10.18632/oncotarget.12999.PubMedPubMedCentralCrossRef

28.

Sullivan JP, Minna JD, Shay JW. Evidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy. Cancer Metastasis Rev. 2010;29(1):61–72. https://doi.org/10.1007/s10555-010-9216-5.CrossRefPubMedPubMedCentral

29.

Shah SP, Roth A, Goya R, Oloumi A, Ha G, Zhao Y, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403):395–9. https://doi.org/10.1038/nature10933.CrossRefPubMed

30.

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–52. https://doi.org/10.1038/nature10983.CrossRefPubMedPubMedCentral

31.

Ball SG, Shuttleworth A, Kielty CM. Inhibition of platelet-derived growth factor receptor signaling regulates OCT4 and Nanog expression, cell shape, and mesenchymal stem cell potency. Stem Cells. 2012;30(3):548–60. https://doi.org/10.1002/stem.1015.CrossRefPubMedPubMedCentral

32.

Yong X, Tang B, Xiao YF, Xie R, Qin Y, Luo G, et al. Helicobacter pylori upregulates Nanog and OCT4 via Wnt/beta-catenin signaling pathway to promote cancer stem cell-like properties in human gastric cancer. Cancer Lett. 2016;374(2):292–303. https://doi.org/10.1016/j.canlet.2016.02.032.CrossRefPubMed

33.

Li W, Zhou Y, Zhang X, Yang Y, Dan S, Su T, et al. Dual inhibiting OCT4 and AKT potently suppresses the propagation of human cancer cells. Sci Rep. 2017;7:46246. https://doi.org/10.1038/srep46246.CrossRefPubMedPubMedCentral

34.

Wuebben EL, Rizzino A. The dark side of SOX2: cancer—a comprehensive overview. Oncotarget. 2017;8(27):44917–43. https://doi.org/10.18632/oncotarget.16570.CrossRefPubMedPubMedCentral

35.

Liu K, Xie F, Gao A, Zhang R, Zhang L, Xiao Z, et al. SOX2 regulates multiple malignant processes of breast cancer development through the SOX2/miR-181a-5p, miR-30e-5p/TUSC3 axis. Mol Cancer. 2017;16(1):62. https://doi.org/10.1186/s12943-017-0632-9.CrossRefPubMedPubMedCentral

36.

Schaefer T, Wang H, Mir P, Konantz M, Pereboom TC, Paczulla AM, et al. Molecular and functional interactions between AKT and SOX2 in breast carcinoma. Oncotarget. 2015;6(41):43540–56. https://doi.org/10.18632/oncotarget.6183.CrossRefPubMedPubMedCentral

37.

Singh SK, Chen NM, Hessmann E, Siveke J, Lahmann M, Singh G, et al. Antithetical NFATc1-SOX2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. EMBO J. 2015;34(4):517–30. https://doi.org/10.15252/embj.201489574.CrossRefPubMedPubMedCentral

38.

Hui K, Gao Y, Huang J, Xu S, Wang B, Zeng J, et al. RASAL2, a RAS GTPase-activating protein, inhibits stemness and epithelial–mesenchymal transition via MAPK/SOX2 pathway in bladder cancer. Cell Death Dis. 2017;8(2):e2600. https://doi.org/10.1038/cddis.2017.9.CrossRefPubMedPubMedCentral

39.

Wang S, Tie J, Wang R, Hu F, Gao L, Wang W, et al. SOX2, a predictor of survival in gastric cancer, inhibits cell proliferation and metastasis by regulating PTEN. Cancer Lett. 2015;358(2):210–9. https://doi.org/10.1016/j.canlet.2014.12.045.CrossRefPubMed

40.

Yamawaki K, Ishiguro T, Mori Y, Yoshihara K, Suda K, Tamura R, et al. SOX2-dependent inhibition of p21 is associated with poor prognosis of endometrial cancer. Cancer Sci. 2017;108(4):632–40. https://doi.org/10.1111/cas.13196.CrossRefPubMedPubMedCentral

41.

Shen L, Huang X, Xie X, Su J, Yuan J, Chen X. High expression of SOX2 and OCT4 indicates radiation resistance and an independent negative prognosis in cervical squamous cell carcinoma. J Histochem Cytochem. 2014;62(7):499–509. https://doi.org/10.1369/0022155414532654.CrossRefPubMedPubMedCentral

42.

Tang XB, Shen XH, Li L, Zhang YF, Chen GQ. SOX2 overexpression correlates with poor prognosis in laryngeal squamous cell carcinoma. Auris Nasus Larynx. 2013;40(5):481–6. https://doi.org/10.1016/j.anl.2013.01.003.CrossRefPubMed

43.

Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer. 2008;98(4):824–31. https://doi.org/10.1038/sj.bjc.6604193.CrossRefPubMedPubMedCentral

44.

Chen Y, Huang Y, Zhu L, Chen M, Huang Y, Zhang J, et al. SOX2 inhibits metastasis in gastric cancer. J Cancer Res Clin Oncol. 2016;142(6):1221–30. https://doi.org/10.1007/s00432-016-2125-4.CrossRefPubMed

Title: OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer
Authors: Jia-Ming Zhang
Kai Wei
Ming Jiang
Publication date: 01-07-2018
Publisher: Springer Japan
Published in: Breast Cancer / Issue 4/2018
Print ISSN: 1340-6868
Electronic ISSN: 1880-4233
DOI: https://doi.org/10.1007/s12282-018-0844-x

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2018

The long and winding road for overcoming resistance to hormone therapy in breast cancer

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

Preoperative breast MRI: reproducibility and significance of findings relevant to nipple–areolar complex involvement

Do you know how to get the J-START quality assurance guideline?

Effect of the normal mammary differentiation regulator ELF5 upon clinical outcomes of triple negative breast cancers patients

Diagnosis, characteristics, and treatment of breast carcinomas within benign fibroepithelial tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer